Diederich Nico J, Moore Charity G, Leurgans Sue E, Chmura Teresa A, Goetz Christopher G
Department of Neuroscience, Centre Hospitalier de Luxembourg, Luxembourg.
Arch Neurol. 2003 Apr;60(4):529-33. doi: 10.1001/archneur.60.4.529.
To our knowledge, no prior study has focused on subjects with Parkinson disease (PD) with elderly disease onset, and there is little evidence-based knowledge of treatment outcomes in these patients.
To compare the clinical presentation, comorbidities, treatment, and evolution of PD in patients with old-age onset with those of patients with middle-age onset in one US university center.
In the Rush Movement Disorder Database, we retrieved 43 patients with PD with onset at 78 years or older. By using a case-control design, we assigned each patient with old-age PD onset 1 (n = 5) or 2 (n = 38) patients with middle-age PD onset, matched for disease duration but with disease onset between the ages of 43 and 66 years. We compared the groups on several clinical measures using conditional logistic regression.
At a comparable length of PD duration (mean, 5.1 years for patients with old-age PD onset and 5.5 years for patients with middle-age PD onset), the total Unified Parkinson's Disease Rating Scale motor score was significantly higher in those with old-age PD onset than in those with middle-age PD onset (33.3 vs 21.2; P<.001). The patients with old-age onset had higher scores for rigidity (5.2 vs 4.3; P =.03), bradykinesia (13.0 vs 9.6; P =.001), and axial impairment (12.8 vs 5.2; P<.001), but not for tremor (2.2 vs 2.0; P =.68). They were more likely to have at least one comorbid condition compared with patients with middle-age onset (24 [56%] of 43 patients vs 20 [25%] of 81 patients; P =.002), but even when adjusting for comorbidities, they still maintained higher motor scores than controls. When treating patients with old-age PD onset, clinicians used levodopa monotherapy more frequently than in patients with middle-age PD onset (34 patients [79%] vs 16 patients [20%]; P<.001), and agonists were prescribed less frequently (5 patients [12%] vs 29 patients [36%]; P =.005).
At the same disease duration, patients with old-age PD onset have greater motor impairment than patients with middle-age PD onset. This difference may be due to more rapid disease progression, less aggressive or less potent medical treatment, the elderly age of the subjects with old-age PD onset at study end independent of disease onset, or yet-to-be elucidated influences of comorbid conditions. Focused research on old-age PD onset is important to delineate the confounding influences of aging and comorbidities and to establish the safety and efficacy of new treatments for this group of patients.
据我们所知,此前尚无研究聚焦于老年发病的帕金森病(PD)患者,并且对于这些患者治疗结果的循证知识也很少。
在美国一所大学中心比较老年发病的PD患者与中年发病的PD患者的临床表现、合并症、治疗及病情演变情况。
在拉什运动障碍数据库中,我们检索出43例发病年龄在78岁及以上的PD患者。采用病例对照设计,为每例老年PD发病患者分配1名(n = 5)或2名(n = 38)中年PD发病患者,二者病程匹配,但发病年龄在43至66岁之间。我们使用条件逻辑回归在多项临床指标上对两组进行比较。
在可比的PD病程长度下(老年PD发病患者平均为5.1年,中年PD发病患者平均为5.5年),老年PD发病患者的帕金森病统一评分量表运动总分显著高于中年PD发病患者(33.3对21.2;P <.001)。老年发病患者在强直(5.2对4.3;P =.03)、运动迟缓(13.0对9.6;P =.001)和轴性损害(12.8对5.2;P <.001)方面得分更高,但在震颤方面得分无差异(2.2对2.0;P =.68)。与中年发病患者相比,他们更有可能至少有一种合并症(43例患者中有24例[56%],81例患者中有20例[25%];P =.002),但即使对合并症进行调整后,他们的运动评分仍高于对照组。在治疗老年PD发病患者时,临床医生比治疗中年PD发病患者更频繁地使用左旋多巴单药治疗(34例患者[79%]对16例患者[20%];P <.001),而使用激动剂的频率较低(5例患者[12%]对29例患者[36%];P =.005)。
在相同病程时,老年PD发病患者比中年PD发病患者有更严重的运动损害。这种差异可能是由于疾病进展更快、医疗治疗不够积极或效果不佳、研究结束时老年PD发病患者的高龄独立于疾病发病因素,或者是合并症尚未阐明的影响。针对老年PD发病进行重点研究对于明确衰老和合并症的混杂影响以及确定针对这组患者的新治疗方法的安全性和有效性很重要。